Literature DB >> 16213532

Screening the receptorome for plant-based psychoactive compounds.

Kerry Ann O'Connor1, Bryan L Roth.   

Abstract

Throughout time, humans have used psychoactive plants and plant-derived products for spiritual, therapeutic and recreational purposes. Furthermore, the investigation of psychoactive plants such as Cannabis sativa (marijuana), Nicotiana tabacum (tobacco) and analogues of psychoactive plant derivatives such as lysergic acid diethylamide (LSD) have provided insight into our understanding of neurochemical processes and diseases of the CNS. Currently, many of these compounds are being used to treat a variety of diseases, such as depression and anxiety in the case of Piper methysticum Kava Kava (Martin et al., 2002; Singh and Singh, 2002). G-protein coupled receptors (GPCRs) are the most common molecular target for both psychoactive drugs and pharmaceuticals. The "receptorome" (that portion of the genome encoding ligand reception) encompasses more than 8% of the human genome (Roth et al., 2004) and as such provides a large number of possible targets for psychoactive drug interactions. A systematic, comprehensive study is necessary to identify novel active psychoactive plant-based compounds and the molecular targets of known compounds. Herein we describe the development of a high throughput system (HTS) to screen psychoactive compounds against the receptorome and present two examples (Salvia divinorum, the "magic mint" hallucinogen and Banisteriopsis caapi, the main component of Ayahuasca, a psychoactive beverage) where HTS enabled the identification of the molecular target of each compound.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16213532     DOI: 10.1016/j.lfs.2005.09.002

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Discovering active compounds from mixture of natural products by data mining approach.

Authors:  Yi Wang; Yecheng Jin; Chenguang Zhou; Haibin Qu; Yiyu Cheng
Journal:  Med Biol Eng Comput       Date:  2008-03-05       Impact factor: 2.602

Review 2.  Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources.

Authors:  Will C McClatchey; Gail B Mahady; Bradley C Bennett; Laura Shiels; Valentina Savo
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

Review 3.  The globalization of traditional medicine in northern peru: from shamanism to molecules.

Authors:  Rainer W Bussmann
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-28       Impact factor: 2.629

4.  Presynaptic CB(1) cannabinoid receptors control frontocortical serotonin and glutamate release--species differences.

Authors:  Samira G Ferreira; Filipe M Teixeira; Pedro Garção; Paula Agostinho; Catherine Ledent; Luísa Cortes; Ken Mackie; Attila Köfalvi
Journal:  Neurochem Int       Date:  2012-05-17       Impact factor: 3.921

Review 5.  Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.

Authors:  Nikhil Neelkantan; Alina Mikhaylova; Adam Michael Stewart; Raymond Arnold; Visar Gjeloshi; Divya Kondaveeti; Manoj K Poudel; Allan V Kalueff
Journal:  ACS Chem Neurosci       Date:  2013-08-06       Impact factor: 4.418

6.  Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors.

Authors:  R Capasso; F Borrelli; M G Cascio; G Aviello; K Huben; J K Zjawiony; P Marini; B Romano; V Di Marzo; F Capasso; A A Izzo
Journal:  Br J Pharmacol       Date:  2008-07-14       Impact factor: 8.739

7.  Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain.

Authors:  Arieh Moussaieff; Neta Rimmerman; Tatiana Bregman; Alex Straiker; Christian C Felder; Shai Shoham; Yoel Kashman; Susan M Huang; Hyosang Lee; Esther Shohami; Ken Mackie; Michael J Caterina; J Michael Walker; Ester Fride; Raphael Mechoulam
Journal:  FASEB J       Date:  2008-05-20       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.